PE20090900A1 - Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene - Google Patents
Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contieneInfo
- Publication number
- PE20090900A1 PE20090900A1 PE2008001322A PE2008001322A PE20090900A1 PE 20090900 A1 PE20090900 A1 PE 20090900A1 PE 2008001322 A PE2008001322 A PE 2008001322A PE 2008001322 A PE2008001322 A PE 2008001322A PE 20090900 A1 PE20090900 A1 PE 20090900A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfanil
- triazolopyridacine
- met
- growth factor
- benzotiazole
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
REFERIDO A UN COMPUESTO DERIVADO DE 6-TRIAZOLOPIRIDACINA-SULFANIL BENZOTIAZOL Y BENCIMIDAZOL DE FORMULA (I): DONDE --- ES UN ENLACE SIMPLE O DOBLE; Ra ES H, HALOGENO, ALCOXI, ENTRE OTROS; X ES S, SO o SO2; A ES NH O S; W ES H, ALQUILO SUSTITUIDO CON ALCOXI, HETEROCICLOALQUILO, NR3R4 O COR; R ES CICLOALQUILO O ALQUILO SUSTITUIDO OPCIONALMENTE CON NR3R4, ALCOXI, HIDROXI ENTRE OTROS; R3 Y R4 SON CADA UNO H, ALQUILO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (6-{[6-(4-FLUOROFENIL)[1,2,4]TRIAZOLO[4,3-b]PIRIDACIN-3-IL]SULFANIL}-1,3-BENZOTIAZOL-2-IL)CARBAMATO DE METILO, 6-{[6-(4-FLUOROFENIL)[1,2,4]TRIAZOLO[4,3-b]PIRIDACIN-3-IL]SULFANIL}-1,3-BENZOTIAZOL-2-AMINA, 1-(6-{[6-(4-FLUOROFENIL)[1,2,4]TRIAZOLO[4,3-b]PIRIDACIN-3-IL]SULFANIL}-1H-BENCIMIDAZOL-2-IL)-3-(2-MORFOLIN-4-ILETIL)UREA. TAMBIEN SE REFIERE A UNA FORMULACION Y A UN METODO DE PREPARACION. DICHO COMPUESTO ES INHIBIDOR DE MET (RECEPTOR DEL FACTOR DE CRECIEMIENTO DE HEPATOCITOS) SIENDO UTIL EN EL TRATAMIENTO ANTIPROLIFERATIVO Y ANTIMETASTASICO, PRINCIPALMENTE EN ONCOLOGIA
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0705789A FR2919870B1 (fr) | 2007-08-09 | 2007-08-09 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzothiazole et benzimidazole, procede, compositions pharmaceutiques et nouvelle utilisation comme inhibiteurs de cmet |
| FR0801819A FR2929613B1 (fr) | 2008-04-02 | 2008-04-02 | Nouveaux derives de 6-triazolopyridazine-sulfanyl benzothiazole et benzimidazole,leur preparation,comme medicaments et utilisation notamment comme inhibiteurs de met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090900A1 true PE20090900A1 (es) | 2009-08-06 |
Family
ID=40524792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001322A PE20090900A1 (es) | 2007-08-09 | 2008-08-07 | Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene |
Country Status (41)
| Country | Link |
|---|---|
| US (3) | US8546393B2 (es) |
| EP (1) | EP2178881B1 (es) |
| JP (1) | JP5694767B2 (es) |
| KR (1) | KR101654376B1 (es) |
| CN (1) | CN101801973B (es) |
| AR (1) | AR068055A1 (es) |
| AU (1) | AU2008320791B2 (es) |
| BR (1) | BRPI0815606A2 (es) |
| CA (2) | CA2695628C (es) |
| CL (1) | CL2008002351A1 (es) |
| CO (1) | CO6251270A2 (es) |
| CR (1) | CR11252A (es) |
| CY (1) | CY1114906T1 (es) |
| DK (1) | DK2178881T3 (es) |
| DO (1) | DOP2010000040A (es) |
| EA (1) | EA023465B1 (es) |
| EC (1) | ECSP109944A (es) |
| ES (1) | ES2436657T3 (es) |
| GT (1) | GT201000023A (es) |
| HR (1) | HRP20131182T1 (es) |
| IL (1) | IL203734A (es) |
| JO (1) | JO2935B1 (es) |
| MA (1) | MA31685B1 (es) |
| ME (1) | ME00972B (es) |
| MX (2) | MX340060B (es) |
| MY (1) | MY152535A (es) |
| NI (1) | NI201000022A (es) |
| NZ (1) | NZ583177A (es) |
| PA (1) | PA8792501A1 (es) |
| PE (1) | PE20090900A1 (es) |
| PL (1) | PL2178881T3 (es) |
| PT (1) | PT2178881E (es) |
| RS (1) | RS53078B (es) |
| SG (1) | SG183077A1 (es) |
| SI (1) | SI2178881T1 (es) |
| TN (1) | TN2010000026A1 (es) |
| TW (1) | TWI429649B (es) |
| UA (1) | UA101328C2 (es) |
| UY (1) | UY31277A1 (es) |
| WO (1) | WO2009056692A2 (es) |
| ZA (1) | ZA201000912B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
| FR2945806B1 (fr) * | 2009-05-19 | 2013-04-05 | Sanofi Aventis | Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met |
| FR2941229B1 (fr) * | 2009-01-21 | 2012-11-30 | Sanofi Aventis | Nouveaux derives triazolo°4,3-a!pyridine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met |
| CN102159559A (zh) * | 2008-07-18 | 2011-08-17 | 赛诺菲-安万特 | 新型咪唑并[1,2-a]吡啶衍生物、其制备方法、其作为药物的用途、其药物组合物和新型用途特别是作为MET抑制剂的新型用途 |
| MX2011000671A (es) * | 2008-07-18 | 2011-04-11 | Sanofi Aventis | Nuevos derivados de triazolo [4,3-a] piridina su procedimiento de preparacion, su uso como medicamentos, composiciones farmaceuticas y nuevo uso particularmente como inhibidores de met. |
| UY32049A (es) | 2008-08-14 | 2010-03-26 | Takeda Pharmaceutical | Inhibidores de cmet |
| FR2941951B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941950B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941952B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| FR2941949B1 (fr) * | 2009-02-06 | 2011-04-01 | Sanofi Aventis | Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met. |
| WO2010092371A1 (en) * | 2009-02-10 | 2010-08-19 | Astrazeneca Ab | Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer |
| US20100292222A1 (en) * | 2009-05-11 | 2010-11-18 | Astrazeneca Ab | Chemical compounds 751 |
| HRP20221090T1 (hr) | 2009-12-31 | 2022-11-25 | Hutchison Medipharma Limited | Određeni triazolopirazini, njihovi pripravci i postupci njihove upotrebe |
| TW201202242A (en) | 2010-03-30 | 2012-01-16 | Sanofi Aventis | 6-(alkyl-or cycloalkyl-triazolopyridazine-sulfanyl)benzo-thiazole derivatives: preparation, and use as medicaments and as MET inhibitors |
| FR2966151B1 (fr) * | 2010-10-14 | 2012-11-09 | Sanofi Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| FR2958292A1 (fr) * | 2010-03-30 | 2011-10-07 | Sanofi Aventis | Derives de 6-(alkyl- ou cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles: preparation, application comme medicaments et utilisation comme inhibiteurs de met |
| WO2012003338A1 (en) | 2010-07-01 | 2012-01-05 | Takeda Pharmaceutical Company Limited | COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET |
| AR085183A1 (es) * | 2010-07-30 | 2013-09-18 | Lilly Co Eli | Compuesto 6-(1-metil-1h-pirazol-4-il)-3-(2-metil-2h-indazol-5-iltio)-[1,2,4]triazol[4,3-b]piridazina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar cancer |
| UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
| WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| MA37753B1 (fr) * | 2012-07-12 | 2019-04-30 | Sanofi Sa | Composition antitumorale comprenant le composé 1-(6-{[6-(4-fluorophényl)[1,2,4]triazolo[4,3-b] pyridazin-3-yl]sulfanyl}-1,3-benzothiazol-2-yl)-3-(2-morpholin-4-yléthyl)urée |
| JP2015537017A (ja) | 2012-11-19 | 2015-12-24 | バイエル ファーマ アクチエンゲゼルシャフト | アミノイミダゾピリダジン類 |
| TWI695837B (zh) | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| EP3229836B1 (en) | 2014-12-09 | 2019-11-13 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Human monoclonal antibodies against axl |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| US10047071B1 (en) | 2018-01-15 | 2018-08-14 | King Saud University | Dihydropyrimidinone derivatives |
| CN110317216A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑并哒嗪类衍生物在医药领域的应用 |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| CN110041311B (zh) * | 2019-05-20 | 2021-03-19 | 东南大学 | 一种荧光探针分子ml-fp及其制备方法和应用 |
| JP2022536489A (ja) * | 2019-06-12 | 2022-08-17 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶性塩形態 |
| US20220401436A1 (en) | 2019-11-08 | 2022-12-22 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2499995A1 (fr) | 1981-02-13 | 1982-08-20 | Roussel Uclaf | Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkylthiomethyl 7-amino thiazolylacetamido cephalosporanique, leur preparation, leur application comme medicaments, les compositions les renfermant et les nouveaux intermediaires obtenus. |
| NZ510013A (en) * | 1998-09-11 | 2003-11-28 | Warner Lambert Co | Dihydropyrones with selected heterocycles replacing the phenyls bearing polar substituents used as HIV protease inhibitors |
| EP1298125A1 (en) | 2001-09-26 | 2003-04-02 | Aventis Pharma S.A. | Substituted benzimidazole compounds and their use for the treatment of cancer |
| WO2007064797A2 (en) * | 2005-11-30 | 2007-06-07 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-met and uses thereof |
| KR101412675B1 (ko) * | 2005-12-21 | 2014-07-03 | 얀센 파마슈티카 엔.브이. | 티로신 키나제 모듈레이터로서의 트리아졸로피리다진 |
| CA2651979A1 (en) * | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Triazolopyridazine derivatives |
| PE20080403A1 (es) * | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| DK2084162T3 (da) * | 2006-10-23 | 2012-10-01 | Sgx Pharmaceuticals Inc | Bicykliske triazoler som proteinkinasemodulatorer |
| PA8792501A1 (es) | 2007-08-09 | 2009-04-23 | Sanofi Aventis | Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met. |
-
2008
- 2008-08-05 PA PA8792501A patent/PA8792501A1/es unknown
- 2008-08-06 MY MYPI2010000582A patent/MY152535A/en unknown
- 2008-08-06 ES ES08845285T patent/ES2436657T3/es active Active
- 2008-08-06 RS RSP20130542 patent/RS53078B/en unknown
- 2008-08-06 KR KR1020107005087A patent/KR101654376B1/ko active IP Right Grant
- 2008-08-06 MX MX2014000226A patent/MX340060B/es unknown
- 2008-08-06 CA CA2695628A patent/CA2695628C/fr not_active Expired - Fee Related
- 2008-08-06 EA EA201070235A patent/EA023465B1/ru not_active IP Right Cessation
- 2008-08-06 BR BRPI0815606 patent/BRPI0815606A2/pt active Search and Examination
- 2008-08-06 MX MX2010001593A patent/MX2010001593A/es active IP Right Grant
- 2008-08-06 EP EP08845285.9A patent/EP2178881B1/fr active Active
- 2008-08-06 NZ NZ583177A patent/NZ583177A/en not_active IP Right Cessation
- 2008-08-06 SG SG2012055091A patent/SG183077A1/en unknown
- 2008-08-06 ME MEP-2010-7A patent/ME00972B/me unknown
- 2008-08-06 SI SI200831106T patent/SI2178881T1/sl unknown
- 2008-08-06 CN CN200880106250.6A patent/CN101801973B/zh not_active Expired - Fee Related
- 2008-08-06 WO PCT/FR2008/001172 patent/WO2009056692A2/fr active Application Filing
- 2008-08-06 AU AU2008320791A patent/AU2008320791B2/en not_active Ceased
- 2008-08-06 JP JP2010519489A patent/JP5694767B2/ja not_active Expired - Fee Related
- 2008-08-06 DK DK08845285T patent/DK2178881T3/da active
- 2008-08-06 PT PT08845285T patent/PT2178881E/pt unknown
- 2008-08-06 CA CA2884102A patent/CA2884102A1/fr not_active Abandoned
- 2008-08-06 PL PL08845285T patent/PL2178881T3/pl unknown
- 2008-08-06 UA UAA201002523A patent/UA101328C2/uk unknown
- 2008-08-07 AR ARP080103452 patent/AR068055A1/es unknown
- 2008-08-07 JO JO2008361A patent/JO2935B1/en active
- 2008-08-07 PE PE2008001322A patent/PE20090900A1/es not_active Application Discontinuation
- 2008-08-07 TW TW97130120A patent/TWI429649B/zh not_active IP Right Cessation
- 2008-08-08 UY UY31277A patent/UY31277A1/es not_active Application Discontinuation
- 2008-08-08 CL CL2008002351A patent/CL2008002351A1/es unknown
-
2010
- 2010-01-13 TN TNP2010000026A patent/TN2010000026A1/fr unknown
- 2010-01-26 US US12/693,736 patent/US8546393B2/en active Active
- 2010-01-28 GT GT201000023A patent/GT201000023A/es unknown
- 2010-01-28 DO DO2010000040A patent/DOP2010000040A/es unknown
- 2010-01-29 CO CO10009506A patent/CO6251270A2/es active IP Right Grant
- 2010-02-03 NI NI201000022A patent/NI201000022A/es unknown
- 2010-02-03 CR CR11252A patent/CR11252A/es unknown
- 2010-02-04 IL IL20373410A patent/IL203734A/en not_active IP Right Cessation
- 2010-02-08 EC ECSP109944 patent/ECSP109944A/es unknown
- 2010-02-08 ZA ZA2010/00912A patent/ZA201000912B/en unknown
- 2010-03-01 MA MA32659A patent/MA31685B1/fr unknown
-
2013
- 2013-08-27 US US14/011,110 patent/US9115134B2/en not_active Expired - Fee Related
- 2013-12-12 HR HRP20131182AT patent/HRP20131182T1/hr unknown
- 2013-12-13 CY CY20131101130T patent/CY1114906T1/el unknown
-
2015
- 2015-06-04 US US14/731,246 patent/US9321777B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090900A1 (es) | Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene | |
| PE20090773A1 (es) | Derivados de morfolina pirimidina | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| UY29246A1 (es) | Nuevos compuestos | |
| PE20081362A1 (es) | DERIVADOS MORFOLINO PIRIMIDINA COMO INHIBIDORES DE mTOR QUINASA Y PI3K | |
| PE20080403A1 (es) | Derivados heterociclicos fusionados y metodos de uso | |
| UY29703A1 (es) | "inhibidores macrocíclicos del virus de la hepatitis c" | |
| ECSP10010419A (es) | Derivados heterocíclicos de urea y métodos de uso de los mismos-211 | |
| AR059957A1 (es) | DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER. | |
| PE20100138A1 (es) | Derivados de morfolino pirimidina usados en enfermedades relacionadas en mtor quinasa y/o pi3k | |
| PE20090649A1 (es) | DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1 | |
| PE20080948A1 (es) | Derivados de imidazol como moduladores de la senda de hedgehog | |
| PE20061073A1 (es) | Compuestos derivados de piperidinilamida como agentes inhibidores de quinasas | |
| AR054799A1 (es) | Derivados de oxindol | |
| PE20130306A1 (es) | Morfolinopirimidinas y su uso en terapia | |
| PE20060374A1 (es) | Inhibidores de cinasa heterociclicos fusionados | |
| PE20060479A1 (es) | Compuestos heteroaril-aril-ureas como inhibidores de la quinasa | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| BRPI0716171A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
| PE20060573A1 (es) | Derivados de urea ciclicos sustituidos como inhibidores de proteinas quinasas | |
| BRPI0813412B8 (pt) | derivados de benzimidazol, seu uso e composição farmacêutica que os compreende | |
| PE20121471A1 (es) | Derivados de sulfonamida heterociclicos utiles como inhibidores de mek | |
| PE20110560A1 (es) | NUEVOS DERIVADOS DE TRIAZOLO[4,3-a]PIRIDINA, SU PROCEDIMIENTO DE PREPARACION, SU APLICACION COMO MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS Y NUEVA UTILIZACION PARTICULARMENTE COMO INHIBIDORES DE MET | |
| PE20090960A1 (es) | Derivados de quinazolinadiona, su preparacion y sus aplicaciones terapeuticas | |
| PE20130191A1 (es) | Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |